Lubiprostone + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Opioid-induced Bowel Dysfunction
Conditions
Opioid-induced Bowel Dysfunction
Trial Timeline
Dec 1, 2010 → Nov 1, 2011
NCT ID
NCT01298219About Lubiprostone + Placebo
Lubiprostone + Placebo is a phase 3 stage product being developed by Mallinckrodt Pharmaceuticals for Opioid-induced Bowel Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT01298219. Target conditions include Opioid-induced Bowel Dysfunction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03097861 | Phase 3 | Completed |
| NCT01298219 | Phase 3 | Completed |
| NCT00595946 | Phase 3 | Completed |
| NCT00597428 | Phase 3 | Completed |
| NCT00399542 | Phase 3 | Completed |
Competing Products
20 competing products in Opioid-induced Bowel Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Approved | 85 |
| Naldemedine | Shionogi | Phase 1/2 | 41 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Placebo + Naldemedine | Shionogi | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + Usual care | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| Naloxegol + Placebo Oral Capsule | AstraZeneca | Phase 2 | 52 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Methylnaltrexone bromide + Placebo | Pfizer | Phase 2 | 51 |